Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib
Name
44318_2018_Article_BFEMBJ201798359.pdf
Size
8.32 MB
Format
Adobe PDF
Checksum (MD5)
0784e951e350401117c46d86cc938f80
Author(s)
Miettinen, Teemu P.
Peltier, Julien
Härtlova, Anetta
Gierliński, Marek
Jansen, Valerie M.
Trost, Matthias
Björklund, Mikael
Date Issued
April 18, 2018
Journal
The EMBO Journal
Publisher
Nature Publishing Group UK
Citation
The EMBO Journal. 2018 Apr 18;37(10):EMBJ201798359
Version
Final published version
Abstract
Palbociclib is a CDK4/6 inhibitor approved for metastatic estrogen receptor‐positive breast cancer. In addition to G1 cell cycle arrest, palbociclib treatment results in cell senescence, a phenotype that is not readily explained by CDK4/6 inhibition. In order to identify a molecular mechanism responsible for palbociclib‐induced senescence, we performed thermal proteome profiling of MCF7 breast cancer cells. In addition to affecting known CDK4/6 targets, palbociclib induces a thermal stabilization of the 20S proteasome, despite not directly binding to it. We further show that palbociclib treatment increases proteasome activity independently of the ubiquitin pathway. This leads to cellular senescence, which can be counteracted by proteasome inhibitors. Palbociclib‐induced proteasome activation and senescence is mediated by reduced proteasomal association of ECM29. Loss of ECM29 activates the proteasome, blocks cell proliferation, and induces a senescence‐like phenotype. Finally, we find that ECM29 mRNA levels are predictive of relapse‐free survival in breast cancer patients treated with endocrine therapy. In conclusion, thermal proteome profiling identifies the proteasome and ECM29 protein as mediators of palbociclib activity in breast cancer cells.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.15252/embj.201798359
